Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

related to degree

  • Long, Jonathan, Ph.D. in Chemistry, Scripps Research 2007 - 2011

authors

  • Schlosburg, J. E.
  • Carlson, B. L. A.
  • Ramesh, D.
  • Abdullah, R. A.
  • Long, Jonathan
  • Cravatt, Benjamin
  • Lichtman, A. H.

publication date

  • June 2009

journal

  • AAPS Journal  Journal

abstract

  • Abstinence symptoms in cannabis-dependent individuals are believed to contribute to the maintenance of regular marijuana use. However, there are currently no medications approved by the FDA to treat cannabis-related disorders. The only treatment currently shown consistently to alleviate cannabinoid withdrawal in both animals and humans is substitution therapy using the psychoactive constituent of marijuana, Delta(9)-tetrahydrocannabinol (THC). However, new genetic and pharmacological tools are available to increase endocannabinoid levels by targeting fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL), the enzymes responsible for the degradation of the endogenous cannabinoid ligands anandamide and 2-arachidonoylglycerol, respectively. In the present study, we investigated whether increasing endogenous cannabinoids levels, through the use of FAAH (-/-) mice as well as the FAAH inhibitor URB597 or the MAGL inhibitor JZL184, would reduce the intensity of withdrawal signs precipitated by the CB(1) receptor antagonist rimonabant in THC-dependent mice. Strikingly, acute administration of either URB597 or JZL184 significantly attenuated rimonabant-precipitated withdrawal signs in THC-dependent mice. In contrast, FAAH (-/-) mice showed identical withdrawal responses as wild-type mice under a variety of conditions, suggesting that the absence of this enzyme across the development of dependence and during rimonabant challenge does not affect withdrawal responses. Of importance, subchronic administration of URB597 did not lead to cannabinoid dependence and neither URB597 nor JZL184 impaired rotarod motor coordination. These results support the concept of targeting endocannabinoid metabolizing enzymes as a promising treatment for cannabis withdrawal.

subject areas

  • Amidohydrolases
  • Animals
  • Benzamides
  • Benzodioxoles
  • Cannabinoid Receptor Modulators
  • Carbamates
  • Dronabinol
  • Endocannabinoids
  • Enzyme Inhibitors
  • Hallucinogens
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Monoacylglycerol Lipases
  • Motor Activity
  • Piperidines
  • Postural Balance
  • Psychomotor Performance
  • Pyrazoles
  • Substance Withdrawal Syndrome
scroll to property group menus

Research

keywords

  • 2-arachindonoylglycerol (2-AG)
  • anandamide
  • cannabis dependence
  • fatty acid amide hydrolase (FAAH)
  • monoacylglycerol lipase (MAGL)
scroll to property group menus

Identity

PubMed Central ID

  • PMC2691470

International Standard Serial Number (ISSN)

  • 1550-7416

Digital Object Identifier (DOI)

  • 10.1208/s12248-009-9110-7

PubMed ID

  • 19430909
scroll to property group menus

Additional Document Info

start page

  • 342

end page

  • 352

volume

  • 11

issue

  • 2

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support